Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease

被引:17
|
作者
Pileri, Alessandro [1 ,2 ]
Agostinelli, Claudio [3 ]
Sessa, Maurizio [4 ]
Quaglino, Pietro [5 ]
Santucci, Marco [6 ]
Tomasini, Carlo [7 ]
Grandi, Vieri [2 ]
Fava, Paolo [5 ]
Astrua, Chiara [5 ]
Righi, Simona [3 ]
Patrizi, Annalisa [1 ]
Pileri, Stefano A. [8 ,9 ]
Pimpinelli, Nicola [2 ]
机构
[1] Univ Bologna, Dept Expt Diagnost & Specialty Med, Dermatol Unit, Via Massarenti 1, I-40138 Bologna, Italy
[2] Univ Florence, Sch Med, Dermatol Unit, Dept Surg & Translat Med, Florence, Italy
[3] Univ Bologna, Dept Expt Diagnost & Specialty Med, Haematopathol Unit, Bologna, Italy
[4] Univ Naples 2, Sect Pharmacol L Donatelli, Dept Expt Med, Naples, Italy
[5] Univ Turin, Dept Med Sci, Dermatol Unit, Turin, Italy
[6] Univ Florence, Div Anat Pathol, Dept Surg & Translat Med, Sch Med, Florence, Italy
[7] Univ Turin, Dermatopathol Sect, Azienda Osped Citta Salute & Sci, Turin, Italy
[8] European Inst Oncol, Unit Diagnost Haematopathol, Milan, Italy
[9] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy
关键词
Mycosis fungoides; Dendritic cell; Myeloid-derived suppressor cell; Immunohistochemistry; ENDOTHELIAL GROWTH-FACTOR; T-REGULATORY CELLS; SEZARY-SYNDROME; TUMOR MICROENVIRONMENT; NONPARAMETRIC ANALYSIS; CANCER-IMMUNOTHERAPY; LYMPHOMA; SKIN; IMMUNOSURVEILLANCE; MODEL;
D O I
10.1007/s00428-017-2107-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mycosis fungoides (MF) is characterized by a switch from indolent behaviour in the early stages to a worse clinical outcome in the advanced ones. Recently, various studies have investigated the role the microenvironment might play in such a switch. We have analysed the distribution of Langerhans cells, plasmacytoid dendritic cells and myeloid-derived suppressor cells in 46 MF cases in various stages, aiming to assess whether changes occur from early to advanced stage. We have investigated the number of langerin, CD303 and arginase-1 positive cells and their distribution at high power. Data were analysed using t test for continuous variables, chi (2) tests or Fisher's exact test for categorical variables, as well as analysis of covariance. In comparing stages IA/B to IIB, we observed a significant decrease in Langerhans cells (p value 0.03) and a significant increase in CD303 and arginase-1 positive cells (p value < 0.01 for both markers). Furthermore, a significant increase in Langerhans cells only was observed in stage IIB in comparison to stage III (p = 0.02), while in stage IV, a significant decrease in Langerhans cells was noted in comparison to stage III (p = 0.02). Our data suggest that changes in the microenvironment might influence disease progression, especially from stages IA/B to IIB, opening new scenarios in MF therapy.
引用
收藏
页码:575 / 582
页数:8
相关论文
共 50 条
  • [31] Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease
    Crook, Kristen R.
    Jin, Mengyao
    Weeks, Michael F.
    Rampersad, Rishi R.
    Baldi, Robert M.
    Glekas, Amy S.
    Shen, Yajuan
    Esserman, Denise A.
    Little, Paul
    Schwartz, Todd A.
    Liu, Peng
    JOURNAL OF LEUKOCYTE BIOLOGY, 2015, 97 (03) : 573 - 582
  • [32] MYELOID-DERIVED SUPPRESSOR CELLS AND DENDRITIC CELLS FOR IMPAIRED RESPONSE TO VACCINE IN MICE WITH NONALCOHOLIC FATTY LIVER DISEASE
    Akbar, S. M. F.
    Chen, S.
    Al-Mahtab, M.
    Miyake, T.
    Hiasa, Y.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S143 - S144
  • [33] Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease
    Joseph Markowitz
    Taylor R. Brooks
    Megan C. Duggan
    Bonnie K. Paul
    Xueliang Pan
    Lai Wei
    Zachary Abrams
    Eric Luedke
    Gregory B. Lesinski
    Bethany Mundy-Bosse
    Tanios Bekaii-Saab
    William E. Carson
    Cancer Immunology, Immunotherapy, 2015, 64 : 149 - 159
  • [34] Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease
    Markowitz, Joseph
    Brooks, Taylor R.
    Duggan, Megan C.
    Paul, Bonnie K.
    Pan, Xueliang
    Wei, Lai
    Abrams, Zachary
    Luedke, Eric
    Lesinski, Gregory B.
    Mundy-Bosse, Bethany
    Bekaii-Saab, Tanios
    Carson, William E., III
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (02) : 149 - 159
  • [35] In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells. (vol 190, pg 2631, 2013)
    Ioannou, M.
    Alissafi, T.
    Boon, L.
    Boumpas, D.
    Verginis, P.
    JOURNAL OF IMMUNOLOGY, 2014, 192 (03): : 1332 - 1332
  • [36] Respiratory and systemic monocytes, dendritic cells, and myeloid-derived suppressor cells in COVID-19: Implications for disease severity
    Falck-Jones, Sara
    Osterberg, Bjorn
    Smed-Sorensen, Anna
    JOURNAL OF INTERNAL MEDICINE, 2023, 293 (02) : 130 - 143
  • [37] Different TLR signalings generate two distinct types of myeloid-derived suppressor cells during dendritic cell differentiation
    Shin, S. J.
    Kwon, K. W.
    Kim, W. S.
    Kim, H. M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 48 : 134 - 134
  • [38] Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease
    Zoeller, Margot
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [39] High granulocytic myeloid-derived suppressor cell levels in the peripheral blood predict a better IVF treatment outcome
    Zhu, Mengchen
    Huang, Xiaomin
    Yi, Shanling
    Sun, Haixiang
    Zhou, Jianjun
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2019, 32 (07): : 1092 - 1097
  • [40] Decrease in circulating myeloid and plasmacytoid Dendritic Cell Precursors (dcps) in patients with Chronic Kidney Disease stage 3
    Kretzschmar, D.
    Paul, K. P.
    Figulla, H. R. F.
    Wolf, G. W.
    Busch, M. B.
    Yilmaz, A. Y.
    EUROPEAN HEART JOURNAL, 2012, 33 : 750 - 750